Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s196189
Abstract: Purpose: EGFR and anaplastic lymphoma kinase (ALK) alterations have been regarded as oncogenic drivers and incorporated into clinical practices to manage nonsmall cell lung cancer (NSCLC). Alterations of these two genes were traditionally considered to… read more here.
Keywords: egfr alterations; eml4 alk; alk; alk alterations ... See more keywords